CNO insider to sell 9,920 performance shares via Morgan Stanley

Rhea-AI Filing Summary

CNO Financial Group Form 144 discloses a proposed sale of common stock: 9,920 shares with an aggregate market value of $376,551.30, to be executed on the NYSE through Morgan Stanley Smith Barney LLC with an approximate sale date of 08/13/2025. The filing records 96,931,934 shares outstanding.

The shares were acquired from the issuer on 02/15/2024 as performance shares and payment is shown as Not Applicable. The filer reports Nothing to Report for securities sold during the past three months and makes the standard representation that they are not aware of undisclosed material adverse information about the issuer.

Insights

Securities Analyst

TL;DR: Proposed sale of 9,920 CNO common shares ($376,551) via major broker; appears routine and likely immaterial to equity base.

The Form 144 shows a single proposed disposition of 9,920 shares valued at $376,551.30, to be executed on the NYSE through Morgan Stanley Smith Barney LLC. The shares were originally issued as performance shares by the issuer on 02/15/2024. With 96,931,934 shares outstanding reported on the form, this filing represents a small, discrete proposed sale rather than a large-scale liquidation. The filer also reports no sales in the prior three months, suggesting this is an isolated notice rather than part of frequent dispositions.

Corporate Governance Expert

TL;DR: Insider disposition of awarded performance shares disclosed; standard attestation present and no recent sales reported.

The record indicates the securities were granted by the issuer as performance shares and are now proposed for sale through an established broker. The filing contains the required representation that the seller is not aware of undisclosed material adverse information. Absence of reported sales in the prior three months and the form's specific acquisition details (issuer grant on 02/15/2024) are consistent with a routine, compliance-driven disclosure of a planned sale rather than an emergent governance concern.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	9920	376551.30	96931934	08/13/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/15/2024	Performance Shares	ISSUER			9920	02/15/2024	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does CNO's Form 144 disclose?

The filing discloses a proposed sale of 9,920 common shares with aggregate market value of $376,551.30, to be executed on the NYSE via Morgan Stanley Smith Barney LLC on 08/13/2025.

How were the shares being sold acquired?

The shares were acquired from the issuer as performance shares on 02/15/2024, with payment recorded as Not Applicable.

Has the filer sold any CNO securities in the past three months?

The form states Nothing to Report for securities sold during the past three months.

Who is acting as the broker for the proposed sale?

The broker listed is Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.

Does the filing indicate reliance on a Rule 10b5-1 trading plan?

The form includes the standard instruction about Rule 10b5-1 plans but does not provide a date of plan adoption or instruction in the content provided.